Enhanced Intradermal Delivery of Nanosuspensions of Antifilariasis Drugs Using Dissolving Microneedles : A Proof of Concept Study by Permana, Andi Dian et al.
Enhanced Intradermal Delivery of Nanosuspensions of Antifilariasis
Drugs Using Dissolving Microneedles : A Proof of Concept Study
Permana, A. D., McCrudden, M. T. C., & Donnelly, R. F. (2019). Enhanced Intradermal Delivery of





Publisher's PDF, also known as Version of record
Queen's University Belfast - Research Portal:
Link to publication record in Queen's University Belfast Research Portal
Publisher rights
Copyright 2019 the authors.
This is an open access article published under a Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/),
which permits unrestricted use, distribution and reproduction in any medium, provided the author and source are cited.
General rights
Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other
copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated
with these rights.
Take down policy
The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to
ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the
Research Portal that you believe breaches copyright or violates any law, please contact openaccess@qub.ac.uk.
Download date:10. Sep. 2019
pharmaceutics
Article
Enhanced Intradermal Delivery of Nanosuspensions
of Antifilariasis Drugs Using Dissolving
Microneedles: A Proof of Concept Study
Andi Dian Permana 1,2 , Maelíosa T. C. McCrudden 1 and Ryan F. Donnelly 1,*
1 School of Pharmacy, Medical Biology Centre, Queen’s University Belfast, 97 Lisburn Road,
Belfast BT9 7BL, UK
2 Department of Pharmaceutics, Faculty of Pharmacy, Hasanuddin University, Makassar 90234, Indonesia
* Correspondence: r.donnelly@qub.ac.uk; Tel.: +44-028-9097-2251; Fax: +44-028-9024-7794
Received: 25 June 2019; Accepted: 13 July 2019; Published: 17 July 2019


Abstract: Conventional oral administration of antifilariasis drugs results in nonspecific targeting
of the drugs and the intradermal delivery of nanoparticles with sizes of <100 nm could be used to
improve lymphatic uptake. This study investigated the combination of nanosuspension and dissolving
microneedles (MN-NS) as an alternative intradermal delivery approach for the delivery of antifilariasis
drugs, namely doxycycline, albendazole, and ivermectin. NS were fabricated and optimized using
a bottom-up technique. The NS were then incorporated into the MN arrays. The optimized NS
were <100 nm in diameter. Furthermore, MN-NS had suitable mechanical strength and insertion
capabilities. The dermatokinetic study revealed that the delivery of drugs into the dermis of excised
neonatal porcine skin by MNs was significantly higher than that from a needle-free patch, with
29.29 ± 4.65%, 31.54 ± 5.35%, and 34.54 ± 4.98% of doxycycline, albendazole sulfoxide, and ivermectin
retained in the dermis after 24 h. The results presented here serve as proof of concept for the
significant enhancement of drug retention times in the dermis, following their formulation into NS
and delivery via MN. Leading on from these studies, future work must investigate in vivo lymphatic
pharmacokinetic profiling of drugs formulated into NS, in a suitable animal model.
Keywords: doxycycline; albendazole; ivermectin; nanosuspension; microneedles; dermatokinetic;
lymphatic filariasis
1. Introduction
Lymphatic filariasis (LF) is a human parasitic disease caused by the Filarioidea family of nematodes,
triggering damage to the lymphatic system and leading to elephantiasis, hydrocele, and kidney
damage (including chyluria) [1,2]. Nematodes are transmitted to individuals who are bitten by infected
mosquitoes. Aedes, Anopheles, Culex, or Mansonia are the species of mosquitoes that act as intermediate
vectors and hosts of the filarial nematodes. Adult nematodes reside in the lymphatic vessels and
lymph nodes of infected individuals where they can dwell for several years [3]. The endosymbiotic
bacteria, Wolbachia, has been found to live in filarial nematodes. These bacteria have a major role in
the biological life cycles of the nematodes by helping the reproduction and survival of the filarial
nematodes [4]. In 2017, it was reported that 51 countries were still considered to require mass drug
administration (MDA) for LF treatment [1]. The World Health Organization (WHO) has established LF
as one of the world’s leading causes of long-term and permanent disability [1,5].
The current MDA approach to combat LF involves the delivery of a combination of several
antifilariasis drugs/medications. In this approach, albendazole (ABZ), with ivermectin (IVM) are
routinely administered orally to target and kill the nematodes [5,6]. Moreover, the use of doxycycline
Pharmaceutics 2019, 11, 346; doi:10.3390/pharmaceutics11070346 www.mdpi.com/journal/pharmaceutics
Pharmaceutics 2019, 11, 346 2 of 22
(DOX) to target Wolbachia has shown a significant decrease in the number of Wolbachia and microfilariae
in the bloodstream in a human trial [7]. However, despite the fact that these drugs effectively reduce
the viability of microfilariae in the bloodstream, they have limited effects on adult filarial in the lymph
nodes [8]. When administered via this route, the drugs must pass across the epithelium of the intestine
in order to reach the underlying interstitial space drained by the lymph and blood capillaries [9]. As a
result, drug concentrations in the lymphatics, the anatomical site where the adult nematodes dwell
and where drug should be targeted, are severely limited. Consequently, the development of a novel
antifilarial drug formulation and delivery system that could be utilized to target delivery of the drugs
to the site of action, would increase the concentrations of drugs at these sites and thus the effectiveness
of the treatment [10].
Several emerging technologies have been applied in lymph targeting, namely liposomes [11],
polymeric nanoparticles [12], solid lipid nanoparticles [13], self-emulsifying self-nanosuspension drug
delivery systems [14], nanosuspensions (NS) [15], and microneedle (MN) array delivery systems [16].
NS are unique liquid sub-micron colloidal dispersions of pure drug particles stabilized using
an appropriate surfactant and/or polymer and typically have particle sizes of 1–1000 nm [17].
NS technologies are being actively investigated in lymph targeting of a variety of anti-HIV drugs:
lopinavir (LPV), ritonavir, tenofovir (TFV), and lamivudine (3TC) [15]. DOX, ABZ, and IVM are good
candidates of this approach due to their poor solubility. To elaborate on one such novel approach, the
use of NS is undergoing considerable investigation in the production of small particle sizes of poorly
soluble drugs [18]. With respect to the potential route of administration of drugs to specifically target
the lymphatic system, the intradermal route has been found to be the most appropriate route to deliver
drug into the lymph due to higher lymph flow rates in the skin compared to other interstitial sites [9].
It has been reported that due to the characteristics of lymph capillaries, after the administration at
this site, particles with sizes between 10 and 100 nm are taken up by the lymphatic capillaries, while
particles of less than 10 nm are absorbed by blood capillaries [19]. In contrast, particles of more
than 100 nm are retained at the administration site [19]. However, the administration of drugs via
hypodermic needles intradermally could result in several disadvantages, namely pain, needle phobia,
poor patient compliance, and the generation of hazardous biological waste [20]. In addition to this, in
spite of its advantages, intradermal injections are not generally used clinically and it has been reported
that administration of intradermal injection by trained professionals are not always successful [21].
MNs are minimally invasive devices which can by-pass the stratum corneum, the principal skin barrier
to topically-applied drugs, without pain and, as such, are envisioned as novel trans- and intra-dermal
drug delivery systems [22]. MNs are applied to the skin surface and form small aqueous pores
through which drugs penetrate to the dermal microcirculation [22,23]. With a view to exploiting this
novel delivery system in the administration of NS, a number of studies have already evaluated the
lymphatic uptake of drugs using MNs as intradermal delivery vehicles. These studies have shown
increases in drug concentration in the lymph nodes compared to the intravenous and subcutaneous
delivery routes [16,24]. Furthermore, our research group has previously developed MN formulations in
combination with NS to deliver cholecalciferol [25] and rilpivirine [26] intradermally. With reference to
the latter study, using this combinatorial delivery approach, rilpivirine was detected in the lymph nodes
of treated rats, providing justification for the continued exploration of this approach [26]. Leading on
from this, the use of drug NS with particle sizes of ~100 nm, in combination with intradermal delivery,
could potentially be used to target nematode infection sites in lymph nodes for the treatment of LF.
In the present study, we outline the combinatorial approach of using drugs in NS form, with
intradermal delivery of the NS via MN, using an antibacterial drug (DOX) and two antifilariasis drugs
(ABZ and IVM). As the intradermal route prevents drugs undergoing first-pass metabolism in the liver,
albendazole sulfoxide (ABZ-OX), as an active metabolite of ABZ, was used in this study. We developed
and optimized the drug NS using central composite design (CCD) and incorporated the optimized
NS into dissolving MNs. Following mechanical characterization studies of the MN, novel ex vivo
dermatokinetic studies, skin distribution, and deposition studies were carried out. The outcomes of
Pharmaceutics 2019, 11, 346 3 of 22
these proof of principle studies allowed us to form insights into the kinetic profiles of the drugs in
the epidermis and dermis, over the course of different application durations. The results presented
here point towards the potential to retain NS in the dermis layer which could potentially have positive
implications for lymphatic uptake of appropriately formulated drugs.
2. Materials and Methods
2.1. Chemicals and Materials
Doxycycline monohydrate (DOX) (purity, ≥98%) and ivermectin (purity, ≥98%) of analytical grade
were purchased from Alfa Aesar (Lancashire, UK), while chloroform, citric acid, dimethylsulfoxide
(DMSO), albendazole sulfoxide (ABZ-OX) (purity, ≥99.9%), hydroxyl propyl methylcellulose (HPMC),
poly (vinyl alcohol) (PVA) (MW 9–10 kDa), poly (vinyl alcohol) (PVA) (31–50 kDa), sodium
carboxymethylcellulose (NaCMC), sodium hydroxide, and sodium lauryl sulphate (SLS) were
purchased from Sigma-Aldrich (Dorset, UK). Poly (vinyl pyrrolidone) (PVP) (58 kDa) was obtained
from Ashland (Kidderminster, UK). Pluronic® F127 (PF127), Pluronic® F108 (PF108), Pluronic® F68
(PF68) were obtained from BASF SE (Ludwigshafen, Germany). Ultrapure water was obtained from a
water purification system (Elga PURELAB DV 25, Veolia Water Systems, Dublin Ireland). All other
reagents were of analytical grade and purchased from standard commercial suppliers.
2.2. Preparation of NS
The NS were prepared using a bottom-up technique. Two methods were applied, namely the
solvent-antisolvent [27] and acid-base neutralization precipitation method [28] under sonication
(Davidson and Hardy Ltd. Cooperating with Fisher Scientific, Leicestershire, UK), with some
modifications. The solvent-antisolvent precipitation method was employed to formulate DOX and
IVM NS. ABZ-OX NS were prepared using acid-base neutralisation precipitation. Several polymers
and surfactants, including PVP, PVA (MW 9–10 kDa), NaCMC, HPMC, PF127, PF108, PF68, and SLS
were investigated as stabilizers.
2.2.1. Doxycycline Nanosuspensions (DOX NS)
In DOX NS preparation, DMSO was used as a solvent and water containing different concentrations
of stabilizers was used as an antisolvent phase. Initially, doxycycline was dissolved in 1 mL of DMSO
and following this, the drug solution was dropped into 5 mL of antisolvent phase in the probe sonicator
(an amplitude of 80% with 10 s pulse on and 5 s pulse off). All the processes were performed in an
ice bath.
2.2.2. Albendazole Sulfoxide Nanosuspensions (ABZ-OX NS)
With respect to ABZ-OX NS preparation, the drug was dissolved in 1 mL of 0.5 M sodium
hydroxide solution. The drug solution was precipitated in the probe sonicator (an amplitude of 80%
with 10 s pulse on and 5 s pulse off) by adding the dissolved drug into 5 mL of 0.3 M citric acid solution
containing stabilizers. The NS production was carried out in an ice bath.
2.2.3. Ivermectin Nanosuspensions (IVM NS)
In order to formulate IVM NS, the solvent phase was prepared by dissolving IVM in 0.5 mL
of chloroform, while the antisolvent phase was prepared by dissolving the stabilizers in water.
Following this process, the solvent phase was added into 5 mL of the antisolvent in the probe sonicator
(an amplitude of 80% with 10 s pulse on and 5 s pulse off) on an ice bath. Chloroform in the formulation
was removed by stirring the formulation on a magnetic stirrer for 2 h.
In an attempt to remove the residual DMSO from the DOX NS and the stabilizers from all other
NS, the NS were centrifuged (Sigma® 1–14 micro-centrifuge, SciQuip Ltd., Shropshire, UK) at 14,000× g
for 30 min and washed three times with purified water. Prior to the lyophilization process, 5 mL
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of cryoprotectant solution (2.5% w/v of PVP) was added into the free-surfactant NS, as described
previously. These mixtures were pre-frozen at −80 ◦C in an ultra-low temperature freezer for 2 h,
then transferred to the freeze dryer (Virtis Advantage Bench-top Freeze-drier system, SP Scientific,
Warminster, PA, USA) for 26 h to produce dry powder particles. The preparation of NS is described in
Figure 1a.
Figure 1. (a) Schematic representation of nanosuspension (NS) preparation; (b) microneedle (MN)
array preparation; and (c) dermatokinetic, skin distribution and deposition studies.
2.3. Optimization of NS Formulations
Optimization of NS formulations was performed using a CCD with Design Expert Software
version 11 (State-Ease, Minneapolis, MN, USA). Four main factors which affect NS characteristics were
chosen, namely drug concentration, stabilizer concentration, antisolvent volume, and sonication time.
These factors were analyzed on the software at five different levels (−alpha, low, medium, high, +alpha)
and the three responses were then recorded, namely particle size, PDI, and zeta potential. The level
of drug concentration, antisolvent volume and sonication time were similar in all optimizations.
While stabilizer concentration of DOX formulation was different from the ABZ-OX and IVM
formulations. The optimization of the experimental design for the three drugs are shown in Table S1.
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2.4. Characterization of Optimized NS
The determinations of particle sizes, polydispersity indexes (PDI), and zeta potentials of the various
NS were performed using NanoBrook Omni particle sizer and zeta potential analyzer (Brookhaven,
New York, NY, USA). The particle size was expressed in intensity. The morphologies of the NS were
examined using the transmission electron microscope (TEM) (JEM-1400Plus; JEOL, Tokyo, Japan).
Moreover, Fourier transform infrared (FTIR) studies for pure drugs and NS was carried out using
FTIR spectrometer (Accutrac FT/IR-4100™ Series, Jasco, Essex, UK). Differential scanning calorimetry
(DSC) for the pure drugs, physical mixture, the NS was performed using a differential scanning
calorimeter (DSC 2920, TA Instruments, Surry, UK). Finally, the drug contents of each formulation were
analyzed using the validated high-performance liquid chromatography (HPLC) method described in
the analytical section.
2.5. In Vitro Drug Release Study
In vitro release of DOX, ABZ-OX and IVM from NS were carried out using dialysis method [29].
In order to achieve sink conditions, different release media were used based on the solubility of the
drugs. In this study, PBS (pH 7.4), PBS:ethanol (70:30, v/v) and PBS:methanol (50:50, v/v) were used as
the release media for DOX, ABZ-OX, and IVM, respectively. The study was conducted using the pure
drug and the lyophilized NS (equivalent to 5 mg of each drug). The NS (1 mL) was dispersed into the
Spectra-Por®, 12,000–14,000 MWCO dialysis membrane (Spectrum Medical Industries, Los Angeles,
CA, USA). The bags were each suspended in 100 mL of release media at 37 ◦C in an orbital shaker at
100 rpm. At predetermined time intervals, aliquots of 1 mL of sample were taken and replaced by
1 mL fresh release media. To calculate the amount of drug released, the samples were then analyzed
using the HPLC method, as described in the analytical section.
The cumulative drug release was further fitted to different mathematical kinetic models, as
outlined in previous studies: [30]
Zero-order : Qt = Q0 + K0t
Zero-order : Qt = Q0 + K0t
First-order : lnQt = lnQ0 + K1t
Higuchi : Qt = KH
√
t
Korsmeyer-Peppas : Qt = Ktn
Hixson-Crowell : Q1/30 −Q1/3t = Kst
where Qt (%) is the percentage of drug released at the time t, Q0 is the starting value of Qt, t is the time,
n is the diffusion release exponent, K0, K1, KH, Kt, and Ks are the release constants corresponding to
relevant kinetic models. The model parameters were calculated using DDsolver [31].
2.6. Two-Step Casting of MN and Needle-Free Patch
Several formulations were prepared separately in order to optimize the MNs for delivery of
the DOX, ABZ-OX, and IVM in NS. Various aqueous gel formulations were prepared using selected
polymers of various concentrations. The preparation of MNs is described in Figure 1b. Six different
formulations were prepared, consisting of 20% w/w of lyophilized NS of drugs and 50% w/w of PVP
(formulation code A in each formulation); 30% of lyophilized NS of drugs and 50% of PVP (formulation
code B in each formulation); 20% w/w of lyophilized NS of drugs and 15% w/w of PVA (formulation
code C in each formulation); 30% w/w of lyophilized NS of drugs and 15% w/w of PVA (formulation
code D in each formulation); 30% w/w of lyophilized NS of drugs and 15% w/w of PVA and 5% w/w of
PVP (formulation code E in DOX formulation); 40% w/w of lyophilized NS of drugs and 15% w/w of
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PVA and 10% w/w of PVP (formulation code F in each formulation). Initially, the lyophilized NS were
added to the aqueous formulations of selected polymers and mixed until homogenous. Following
this, 100 mg of the aqueous blend was then poured into the MN molds, manufactured using injection
molding, (needle density of 19 × 19, pyramidal needles; 500 µm height and 300 µm width at base
and 300 µm interspacing). A pre-cast dry baseplate (1 × 1 cm2), prepared from 15% w/w PVP (MW
360 kDa) and 1.5% w/w glycerol was placed behind the needles. Finally, the formulations were placed
in a positive pressure chamber and a pressure of 3–4 bar was applied for 15 min to fill the cavity of the
molds. Lastly, the MNs were dried at room temperature for 24 h and were removed from the molds.
The MNs were visually examined using a Leica EZ4D digital light microscope (Leica Microsystems,
Milton Keynes, UK) and scanning electron microscope (SEM) TM3030 (Hitachi, Krefeld, Germany).
For the needle-free patch preparation, similar formulations were prepared. The aqueous blend (100 mg)
was placed on the top of a flat silicon sheet. Afterwards, a pre-cast dry baseplate was attached behind
the formulations and these were allowed to dry at room temperature for 24 h.
2.7. Skin Sample Collection
Excised skin from stillborn piglets was used in ex vivo studies, with full-thickness skin samples
having been obtained less than 24 h post-mortem. Skin samples were kept in sealed petri dishes at
−20 ◦C until use. Prior to the commencement of experiments, hair was removed from the skin using a
disposable razor and the skin was then equilibrated in phosphate buffered saline (PBS), pH 7.4, for
30 min.
2.8. Mechanical and Insertion Properties of MNs
Mechanical testing was performed using a TA-TX2 Texture Analyzer (Stable Microsystem,
Haslmere, UK), as described previously [32]. In order to evaluate the insertion ability of the MNs,
Parafilm®M was used as an artificial skin layer for the MNs insertion study as reported in a previous
study [33]. The insertion ability of the MNs in Parafilm®M and full-thickness porcine skin were also
evaluated using an optical coherence tomography (OCT) microscope (Michelson Diagnostics Ltd.,
Kent, UK), as outlined in previous study [32]. The height of needles inserted was measured using the
imaging software, ImageJ® (National Institute of Health, Bethesda, MD, USA).
2.9. Calculation of Theoretical Drug Content Localized to the Needles
Initially, baseplates were prepared using the optimized formulation of the MN to calculate the
density of the formulation. The drug amount (mg) in the needle tips were calculated using the following
equation [26]:






where N is the number of needle tips (361 tips), a2 is the width of base of the tips (0.3 mm), h is the
height of the tips (0.5 mm), ρ is the density of the dry formulation, and [drug] is the concentration of
drugs in dry formulation (mg drug/mg NS).
2.10. In Vitro Dermatokinetic, Skin Distribution and Deposition Studies
These studies were carried out using Franz diffusion cells [34]. Full-thickness skin used in these
studies were affixed to the Franz diffusion cells using cyanoacrylate glue. PBS pH 7.4 was used in the
receiver compartment and was thermostatically held at 37 ± 1 ◦C with stirring at 600 rpm. The MNs
arrays were then inserted into the skin using manual force for 30 s and a circular stainless-steel weight
of 5.0 g placed on top to hold the MNs in place. The donor compartment and sampling arm was
wrapped using Parafilm M®. The illustration of this study is shown in Figure 1c.
In the dermatokinetic studies, at the requisite sampling time points (15 min, 30 min, 45 min, 1.5 h,
1 h, 2 h, 3 h, 4 h, 5 h, 6 h, and 24 h), the MNs were removed from the full-thickness skin and the skin was
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washed three times with deionized water to remove any excess formulation. Skin sections were then
collected using a biopsy punch (5 mm diameter) (Stiefel, Middlesex, UK). The skin was then placed into
a 1.5 mL microtube and samples were heated in a water bath at 60 ◦C for 2–3 min. The dermal layers
were further manually separated from the epidermis layers using tweezers. Then, 1 mL methanol was
added into each layer and each mixture was homogenized for 10 min at 50 Hz using Tissue Lyser LT
(Qiagen, Ltd., Manchester, UK) to extract the drug from the skin. Finally, a sample of supernatant was
then collected and analyzed using the HPLC method, as described in Section 2.11. The data obtained
were then fitted to a one-compartment open model using PK Solver software [35]. The curve of drug
concentration versus time was made and the mean peak drug concentration (Cmax), the time of Cmax
(tmax), and the area under curve from time 0 h to 24 h (AUC0-t) were all calculated.
In skin distribution and deposition studies, the skin samples were collected at respective sampling
time points. The time points of 1 h, dermis tmax from dermatokinetic study and 24 h were selected
for this study. The samples were collected using a similar procedure to that described previously.
Following this, the samples were flash frozen in liquid nitrogen. The biopsied samples were then
sectioned into 50 µm sections using a Leica CM1900 Cryostat (Leica Microsystems, Nussloch, Germany)
and four consecutive slices were collected into microtubes. This process was continued until the whole
skin was sliced. In order to analyze the amount of drug distributed and deposited into each slice,
300 µL of methanol was added to the tissue sections. Each sample was vortexed for 30 min to dissolve
the drug and the sample was then centrifuged at 14,000× g, 15 min. A sample of supernatant was then
collected and analyzed using the HPLC method, as described in in the analytical section.
2.11. Instrumentation and Chromatographic Condition for Analytical Method
The quantifications of DOX, ABZ-OX, and IVM were performed separately using reversed-phase
HPLC with Phenomenex® Luna C18 (ODS1) column (150 mm × 4.6 mm i.d. with 5 µm particle size)
using an Agilent Technologies 1220 Infinity compacted LC Series consisting of Agilent degasser, Binary
Pump, auto standard injector and Detector (Agilent Technologies UK Ltd., Stockport, UK). The mobile
phases used in all analysis processes were 25 mM sodium dihydrogen phosphate buffer (with 0.1% v/v
TEA, pH 2.5 adjusted using orthophosphoric acid) and methanol (70:30 v/v) for DOX; 25 mM sodium
dihydrogen phosphate buffer (with 0.1% v/v TEA, pH 3 adjusted using orthophosphoric acid), and
methanol (75:25 v/v) for ABZ-OX; and 0.1% v/v of trifluoroacetic acid in water and methanol (5:95 v/v) for
IVM. The injection volume and flow rate were 25 µL and 1 mL/min, respectively and the analyses were
performed at room temperature with UV detection of 271 nm, 295 nm, and 245 nm for DOX, ABZ-OX,
and IVM, respectively. The chromatograms were analyzed using Agilent ChemStation® Software
B.02.01. The analytical methods were validated as per the International Committee of Harmonization
(ICH) 2005.
2.12. Statistical Analysis
The results were expressed as means± standard deviation (SD) of the mean. The data were analysed
using GraphPad Prism® version 6 (GraphPad Software, San Diego, CA, USA). The Mann-Whitney
U test was performed for comparison between drug NS and pure drug, in terms of the drug release
after 24 h, and between MN and needle-free patches, in terms of dermatokinetic parameters of drugs.
The Kruskal-Wallis test with post-hoc Dunn’s test was used for comparison of the mechanical strength
of MNs of all formulations. In all cases, p-value < 0.05 was considered as a significant difference.
3. Results and Discussion
3.1. Preparation of NS and Screening of Stabilizers
In DOX NS preparation, different polymers and surfactants, at a variety of different concentrations
were utilized to produce the NS. Our preliminary studies (Figures S1–S3) exhibited that the NS prepared
from PVP and SLS exhibited smaller particle size compared to the NS prepared from other stabilizers.
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Therefore, the combination of PVP and SLS as stabilizers was selected for the optimization process.
The optimization was performed using central composite design (CCD). In the optimization process,
SLS concentration was kept constant at 0.2% w/v. Whereas, drug concentration, PVP concentration,
antisolvent volume and sonication time were optimized. The software suggested 24 formulations
for the optimization and the responses of dependent variables in NS formulations are exhibited in
Table S2. The results showed that the particle size, PDI, and zeta potential of DOX NS were in the
range of 85.4–1136.3 nm, 0.20–0.83, and –23.43 to –31.32 mV, respectively. Depending upon electrostatic
attraction, the combination of PVP and SLS leads to the formation of a shortened polymer-surfactant
double protecting layer, leading to smaller particle generation [36]. Based on the fit statistical analysis
results, the difference of all predicted R2 from adjusted R2 was less than 0.2. Although the results
exhibit large variability in the particle size results, the p-value of the model was <0.0001. In addition,
there were no other recommendations for the transformation of the data prior to the analysis. The adeq
precision was 17.0647, 13.9614, and 33.5281 for particle size, PDI, and zeta potential, respectively.
As per the requirement in the software, values greater than four are desirable. Accordingly, this model
was used in order to design the optimum formula for DOX NX. The results of fit statistical analysis for
all responses of DOX NS formulation are shown in Table S5.
With respect to ABZ-OX and IVM NS formulations, PF127 solution was found to be an appropriate
stabilizer. The CCD was again used in optimization process. The optimization was carried out for drug
concentration, PF127 concentration, antisolvent volume, and sonication time. In this optimization,
24 formulations were also suggested by the software and the responses of dependent variables in
ABZ-OX and IVM NS formulations are exhibited in Tables S3 and S4, respectively. The results showed
that the particle size of ABZ-OX and IVM NS were in the range of 84.2–1112.4 nm and 87.8–1168.0 nm,
respectively. PDI values obtained were in the range of 0.19–0.76 and 0.20–0.83 for ABZ-OX and IVM
NS, respectively. The zeta potentials were ranging from −12.36 to −19.05 mV, and −12.98 to −20.25 mV
in the case of ABZ-OX and IVM NS, respectively. The stabilization of NS by PF127 may be attributed
to its poly (propylene oxide) (PPO) and poly (ethylene oxide) (PEO) chains [37]. The hydrophobic PPO
chains of Pluronic promotes the polymer to adsorb onto the surface of hydrophobic drugs [38], while
the hydrophilic PEO chains extend into the aqueous phase, providing steric stabilization by inhibiting
the aggregation [39]. Based on the fit statistical analysis results, the difference of all predicted R2 from
adjusted R2 was less than 0.2. As explained in the DOX NS optimization, the p-value of the model was
also found to be <0.0001, despite the variability of the particle size results and no recommendation of
the data transformation was required before the analysis of the data. In addition, the adeq precision of
all designs was greater than four, which were in the range of 13.9614–33.5281. Therefore, these models
were used in order to design the optimum formulae. The results of fit statistical analysis for ABZ-OX
and IVM NS formulations are shown in Table S5.
3.2. Optimization of NS Formulations
3.2.1. Effect of the Parameters on the Particle Size and PDI
The results showed that the particle size and PDI of all optimization processes followed the
quadratic model. In terms of the particle size analysis, the F-value was found to be 20.77, 19.85, and
19.55 for DOX, ABZ-OX, and IVM NS, respectively. The F-value of 14.83, 15.72, and 15.68 were obtained
in PDI analysis for DOX, ABZ-OX, and IVM NS, respectively. Moreover, the p-value of <0.001 was
found in all cases, indicating that the factors selected had a significant effect on the particle size and
PDI. The representative 3D graphs describing the effect of selected parameters on the particle sizes and
PDI are shown in Figure 2.
In terms of parameters observed, drug concentrations were found to have a significant effect on the
particle size and PDI (p-value < 0.001). The results exhibited that the increase in drug concentration was
followed by the increase of particle size and PDI. This might be caused by the drugs supersaturation
phenomenon. High supersaturation was needed in order to produce small and uniform particles
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to accelerate a nucleation rate greater than the rate of crystal growth. However, when the drug
concentration was excessive, a large number of nuclei quickly formed on the interface of solid phase
and liquid phase and slowed the diffusion from solvent to antisolvent, leading to particle adhesion
and larger particle production [40]. Furthermore, the increasing drug concentration may cause the
increasing of the viscosity of the solutions and avoiding particle diffusion [41]. The concentration of
PVP and PF127 as stabilizers also had a significant effect (p-value < 0.001) on particle size and PDI.
The results exhibited that low concentration of stabilizers produced larger particles, potentially caused
by an inadequate amount of stabilizer coating the hydrophobic surfaces of the drugs [27].
The effect of antisolvent volume was also studied. As shown in Tables S2–S4, the increase in
antisolvent volume was followed by decrease of particle size and PDI. Throughout precipitation, the
growth occurs at the same time as the formation of nuclei. Therefore, the increase of the volume
of antisolvent decreased the concentration of particle in the liquid phase and hence prevented the
possibility of agglomeration between each particle in the suspension, contributing to small particle
formation [42]. In addition, it was found that in order to form a small particle, the ABZ-OX and
IVM NS required less antisolvent volume compared to DOX NS. This may be due to the difference in
viscosity of the solvents used to dissolve the drugs. DMSO has a higher viscosity than chloroform or
0.5 M sodium hydroxide solution. The higher viscosity may avoid particle diffusion to form the small
particles [41]. Accordingly, a greater antisolvent volume was required to form smaller particles.
In NS formulation, duration of sonication also plays a major role in the forming of smaller particle
sizes. In this study, it was found that the particle sizes of the NS decreased following an increase in
sonication time as a result of the greater use of energy [43]. However, despite the decrease of particle
size, the increase in sonication time did not exhibit significant effect (p-value > 0.05) on the particle size
of NS.
3.2.2. Effect of the Parameters on Zeta Potential
The results showed that the zeta potential of all optimization processes followed the quadratic
model. With respect to the analysis results, the F-values of 100.30, 96.56, and 68.34 were obtained
for DOX, ABZ-OX, and IVM, respectively. Additionally, the p-values were found to be <0.001 in all
cases, demonstrating that the model was significant. The effects of selected parameters on the zeta
potentials of the NS are illustrated in the 3D graphs in Figure 2. The only factor to shown a significant
effect on the zeta potential of the NS was the stabilizer concentration. In DOX formulation, which
contained SLS 0.2% w/v, the increasing concentration of PVP decreased the value of zeta potential.
It is well-known that SLS is an anionic surfactant with negative charge [44]. Therefore, the increase
in PVP could possibly decrease the charge of dispersions containing SLS. In the ABZ-OX and IVM
formulations, the same trend was observed. PF127 has a higher number of PPO units, resulting in
higher thickness of adsorbed polymer, thus lowering the value of the zeta potential. The decrease of
zeta potential might be caused by the outer shift of the slipping plane, which is extremely crucial in
zeta potential measurement [39].
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Figure 2. (a) Representative response surface plots describing the effect of dependent variables
on the particle size, polydispersity indexes (PDI), and zeta potential of doxycycline (DOX) NS. (b)
Representative response surface plots describing the effect of dependent variables on the particle size,
PDI, and zeta potential of albendazole sulfoxide (ABZ-OX) NS. (c) Representative response surface plots
describing the effect of dependent variables on the particle size, PDI, and zeta potential of ivermectin
(IVM) NS.
3.3. Characterization of Optimized NS
Based on the analysis of the software outputs, optimized formulations were selected for further
investigation. The criteria were set in order to achieve a particle size of less than 100 nm with
high drug content in the formulations. Several solutions were given by the software and ranked
based on the desirability factor. One optimum formulation for each of DOX, ABZ-OX, and IVM was
selected and the NS from the optimization recommendation were prepared in three batches. The high
desirability of the optimum formula was found in these optimizations, which were 0.99, 0.98, and
0.99 for DOX, ABZ-OX, and IVM NS, respectively. The particle sizes of the optimized formulation
were 98.87 ± 9.77 nm, 96.53 ± 8.43 nm, and 98.12 ± 7.76 nm for DOX, ABZ-OX, and IVM, respectively.
The comparison between the predicted values and the actual values is shown in Table S6. The results
revealed that the bias between predicted values and the actual values was ±15%, indicating that the
computationally designed optimization processes had been successful. Regarding the drug content, it
was found that the drug contents of the optimized NS were 0.243 ± 0.03 mg/mg, 0.252 ± 0.02 mg/mg,
and 0.249 ± 0.03 mg/mg of lyophilized NS for DOX, ABZ-OX, and IVM formulations, respectively.
The morphologies of the optimized NS observed by TEM are shown in Figure 3a. These micrographs
showed that the DOX, ABZ-OX, and IVM NS produced were all spherical in shape. The size of these
NS obtained from TEM were ~100 nm, which was in close agreement with the size obtained by the
particle size analyzer.
FTIR analysis (Figure 3b) revealed that DOX showed a major peak at 1527 cm−1 due to aromatic
N–H bending. Multiple characteristic peaks were also observed between 1397 cm−1 and 1682 cm−1
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due to aromatic C=O and C=C stretching. Sharp peaks were observed at 2917 cm−1, 3308 cm−1,
and 3428 cm−1, corresponding to C–H stretching, primary N–H group and primary O–H groups,
respectively. The characteristic peak of ABZ-OX was observed at 1027 cm−1 due to S=O bonding.
Moreover, peaks at 1519 cm−1, 1729 cm−1, and 2972 cm−1 were corresponding to C=N stretching, –COO
bending and C–H stretching, respectively. In IVM spectra, the specific peaks were found at 1186 cm−1,
1715 cm−1, 1729 cm−1, 2949 cm−1, and 3476 cm−1, relating to C–O–C group, C=O bending, aliphatic
ketone C=O, axial deformation of free C-H and free O–H, respectively. The characteristic bands of
DOX, ABZ-OX, and IVM were also observed in FTIR spectra of NS formulations. The presence of all
major functional groups of all drugs in the final formulation confirmed that there were no chemical
interactions between pure drugs and any of the excipients used.
Figure 3c depicts the thermogram profiles of DOX, ABZ-OX, IVM, and their respective NS
formulations. The sharp endothermic peaks at 168 ◦C in DOX, 226 ◦C in ABZ-OX, and 156 ◦C in IVM
corresponded to the melting point of drug crystals. These peaks were also found the physical mixture.
However, these peaks were not observed in NS formulations, indicating the change of the nature of drugs
from crystalline forms to amorphous. This may be caused by the method of preparation of NS. It was
previously reported that the bottom-up method was able to produce amorphous nanoparticles [41].
Figure 3. Transmission electron microscope (TEM) images of the NS of (a.1) DOX; (a.2) ABZ-OX;
and (a.3) IVM at a magnification power of 30,000×. (b) Nanoparticles were imaged using a JEOL
JEM-1400Plus transmission electron microscope, kV = 80. Fourier transform infrared (FTIR) spectra of
DOX, ABZ-OX, IVM, and their NS formulations. (c) Differential scanning calorimetry (DSC) thermogram
of DOX, ABZ-OX, IVM, and their respective physical mixture (PM) and NS formulations.
3.4. In Vitro Drug Release Study
The profiles of in vitro release of drug NS compared to pure drugs are illustrated in Figure 4.
The release profiles of the drug NS revealed that the NS formulations were able to improve the release of
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all drugs. Specifically, after 24 h, the NS achieved 98.43 ± 18.70%, 86.45 ± 14.70%, and 72 ± 14.60% drug
releases for DOX, ABZ-OX, and IVM NS, respectively. In contrast, only 77.43 ± 20.12%, 43.23 ± 9.08%,
and 38.46 ± 8.17% of drugs were released in case of pure DOX, ABZ-OX, and IVM, respectively. Despite
the lower drug release of pure DOX compared to DOX NS, no significant difference (p-value = 0.2562;
not significant statistically) was found between these release profiles after 24 h. However, with respect
to the release profile of ABZ-OX and IVM, drug release profiles from NS were found to be significantly
higher (p-value = 0.0123; p-value < 0.05 and p-value = 0.0181; p-value < 0.05 for ABZ-OX and IVM
formulations, respectively) than that of the pure drugs. The release profiles clearly showed the rapid
diffusion rate of drugs from nanoparticles as a result of the increase in surface areas after reduction of
the particle sizes to nano-size dispersions. Therefore, it is important to bear in mind that lymphatic
uptake of the nanoparticle drugs should be achieved before the dissolution of the NS in the skin layers.
However, the rapid dissolution of NS is unlikely to occur in the skin as the volume of interstitial is
much lower than the volume of release media utilized in this study.
Figure 4. In vitro release profiles of (a) DOX NS, (b) ABZ-OX NS, and (c) IVM NS in comparison with
the pure drug (means ± SD, n = 3).
In order to investigate the kinetic modelling and release mechanism of NS, the release profiles
were fitted to several kinetic models. The kinetic modelling profiles of all drugs are shown in Table 1.
The appropriate release model was selected based on the value of the correlation coefficient of each
model. The release profiles of all drugs exhibited best fit to first order model. This model describes
that the drug release from the formulation matrix depends on the drug concentration within the
matrix [30,45].
Table 1. Kinetic modelling of DOX, ABZ-OX, and IVM release from NS formulations.
Formulation
R2 Value of Kinetic Model
n
Zero Order First Order Higuchi Hixcon-Crowell Korsmeyer-Peppas
DOX NS 0.4360 0.9311 0.5900 0.7032 0.7983 0.311
ABZ-OX NS 0.4486 0.9461 0.6049 0.7611 0.8054 0.314
IVM NS 0.4963 0.9759 0.76 0.8076 0.7891 0.391
3.5. MN Formulations
Several biocompatible polymers were used to fabricate the dissolving MN formulation in an
attempt to load high concentrations of lyophilized NS. Many water-soluble, biocompatible polymers,
such as PVA [46], PVP [47], HA [32], and Gantrez® copolymers [48] have been widely used as
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polymers in the preparation of dissolving MNs. As described in formulation composition previously in
Section 2.6, a plethora of different MN formulations were prepared to achieve the highest possible drug
loading and analyzed with the results of the present study showing that all MNs prepared exhibited
homogenous polymer blends with the resultant MN having sharp needle tips. All formulations
were supported by dry baseplate prepared from 15% w/w PVP (MW 360 kDa) and 1.5% w/w glycerol.
The morphology of selected MNs examined by light microscope and SEM are shown in Figure 5a–f.
In addition to this, MNs containing free drug were also prepared, in order to allow their comparison
with MN containing the drug NS. However, as the hydrophobic drugs did not dissolve in the aqueous
environments of the MN polymers, the incorporation of these free drugs into MNs did not result in
homogeneous distribution of the drug in the arrays and as such, MN lacked any inherent mechanical
strength and so could not be used in further experiments.
Figure 5. Light microscope images of the MN of Formulation E containing (a) 30% w/w of lyophilized
NS of DOX, 15% w/w of PVA, and 5% w/w of PVP; (b) 30% w/w of lyophilized NS of ABZ-OX, 15%
w/w of PVA, and 10% w/w of PVP and (c) 30% w/w of lyophilized NS of IVM, 15% w/w of PVA, and
10% w/w of PVP (C); SEM images of the MN containing drug NS of (d) DOX, (e) ABZ-OX, and (f)
IVM (F); (g) Comparison of the percentage of height reduction of MN needles formulations containing
20% w/w of lyophilized NS of drugs and 50% w/w of PVP (formulation code A in each formulation);
30% of lyophilized NS of drugs and 50% of PVP (formulation code B in each formulation); 20% w/w
of lyophilized NS of drugs and 15% w/w of PVA (formulation code C in each formulation); 30% w/w
of lyophilized NS of drugs and 15% w/w of PVA (formulation code D in each formulation); 30%
w/w of lyophilized NS of drugs and 15% w/w of PVA and 5% w/w of PVP (formulation code E in
DOX formulation); 40% w/w of lyophilized NS of drugs and 15% w/w of PVA and 10% w/w of PVP
(formulation code F in each formulation) (means ± SD, n = 3).
3.6. Mechanical and Insertion Properties of MNs
The capability of a MN array to be effectively inserted is critical to its use, as the stratum corneum
must be penetrated for the MN array to have its effect. Incorporation of drug substances including NS
into the polymeric solution in the fabrication of a dissolving MN array can create either a weakening
or strengthening effect on the MNs [49]. Therefore, mechanical tests must be carried out as an integral
part of initial formulation studies for dissolving MN arrays.
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Mechanical and insertion studies were carried out on all of the MN generated in this study.
The percentage height reductions of needles on the various MN arrays were determined after
application of forces of 32 N/array, equitable to manual compression force [33]. Figure 5g shows
the percentage of height reduction of needles on MN formulated from each of the three candidate
formulations. The results obtained here revealed that the formulation containing the combination of
PVP and PVA with the drug loading of 30% w/w (Formulation E) exhibited the smallest percentage
of height reduction of needles, which was < 10%. The percentage reduction of the needle heights
for Formulation E of DOX, containing 30% w/w of lyophilized NS, 15% w/w of PVA, and 5% w/w of
PVP was significantly lower (p-value < 0.05) compared to all other formulations. In ABZ-OX and
IVM formulations, the percentage reduction of the needle heights for Formulation E containing 30%
w/w of lyophilized NS, 15% w/w of PVA, and 10% w/w of PVP was significantly lower (p-value < 0.05)
compared to all other formulations. In contrast, Formulation A and B containing only PVP and drug
NS showed the highest percentage reduction of the needle heights with the percentage of height
reduction of >30%, indicating poor mechanical properties. Moreover, Formulation C and D containing
only PVA and drug NS exhibited the percentage of height reduction of >10%. The increase of drug
loading to 40% w/w (Formulation F) resulted in a lack of mechanical strength, despite the homogenous
and sharp needles formed. Therefore, Formulation E of each drug was selected for further studies.
In addition to this, it was found that the baseplate used to support the MNs needles did not show
any change after the compression, indicating that the baseplate had sufficient mechanical strength.
The same force was applied to candidate MN formulations to evaluate the insertion ability of the MNs,
using Parafilm®M as a skin model, as previously described [33].
The results of the skin insertion study were in close agreement with those of the mechanical
strength studies. In this evaluation, the same three candidate formulations were able to penetrate three
layers of Parafilm®M. Figure 6a–f shows the insertion ability of the MNs presented as the number
of holes created in each layer of Parafilm®M. The mean thickness of each layer is approximately
126 µm. Therefore, the MNs inserted up to 378 µm, relating to approximately 75.6% of the MN height.
These results suggest that the needle lengths which inserted into the skin model was similar to a
study reported previously [32]. Moreover, these values were similar with previous studies illustrating
the insertion of polymeric MNs into human skin [50]. In addition to this, OCT was also employed
in insertion studies. The selected formulations were evaluated in terms of insertion ability in both
Parafilm®M and full-thickness porcine skin. Several studies have shown the advantages of this
technique in the investigation of MN insertion in Parafilm®M and skin [26,32]. The results are exhibited
in Figure 6g–l. MN penetration depth of Formulation E in Parafilm®M were found to be 369.12 ± 18.43
µm, 371.88 ± 19.19 µm, and 370.17 ± 17.13 µm for DOX, ABZ-OX, and IVM formulations, respectively.
These insertion depths were in close agreement with those observed in similar studies carried out in
full-thickness, showing depths of 368.17 ± 16.33 µm, 372.03 ± 19.87 µm, and 369.22 ± 13.93 µm for
DOX, ABZ-OX, and IVM formulations, respectively.
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Figure 6. Number of Parafilm®M layers inserted, approximate insertion depths and percentage of
holes created in Parafilm®M layer using an insertion force of 32 N/array using the Texture Analyzer
for MN formulations containing DOX NS (a,b), ABZ-OX NS (c,d), and IVM NS (e,f) (means ± SD,
n = 3). Representative optical coherence tomography (OCT) images of MNs containing (g) DOX NS,
(h) ABZ-OX NS, and (i) IVM NS following insertion into Parafilm®M film. Representative OCT images
of MNs containing (j) DOX NS, (k) ABZ-OX NS, and (l) IVM NS following insertion into full-thickness
porcine skin. The white scale bar represents a length of 1 mm.
3.7. Drug Content Located in the Needles
Upon drying, the amount of drug located in each array was found to be 1.00 ± 0.15 mg,
0.87 ± 0.09 mg, and 0.86 ± 0.07 mg for DOX, ABZ-OX and IVM, respectively.
3.8. In Vitro Dermatokinetic, Skin Distribution and Deposition Studies
Dermatokinetic studies were then carried out in order to evaluate the kinetic profile of drugs
following MNs application in epidermis and dermis layer. Several studies have been conducted
to investigate dermatokinetic profiles of drug delivery systems [34,51]. However, to the best of our
knowledge, the work presented here is the first study investigating the dermatokinetic profile of drugs
following MNs administration. The results show that the concentration of drugs in epidermis and
dermis layer was significantly improved by using dissolving MNs compared to the needle-free patch
(p-value < 0.05). Upon insertion of the MN arrays into the skin, the needles absorb the interstitial fluid
and hence this fluid hydrates the polymer. Therefore, the polymer hydration and dissolution help
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the moving of the drug NS, which is then able to penetrate into the skin. Figure 7a–f describe the
comparison of epidermal and dermal drug profile following MNs application in comparison with the
needle-free patch.
The results of the DOX NS dermatokinetic profile after MNs administration indicated that
the mean peak skin concentration (Cmax) in the epidermis was 266.31 ± 42.73 µg/cm3 within
1.28 ± 0.23 h. In the dermis layer, the maximum concentration of 409.63 ± 54.11 µg/cm3 was found after
3.47 ± 0.49 h. The AUC0–24 of DOX in the epidermis and dermis were 1978.90 ± 232.31 h.µg/cm3 and
6806.79± 790.54 h.µg/cm3, respectively. After MNs administration of ABZ-OX NS, 101.78± 21.32µg/cm3
was found as the maximum concentration within 1.19 ± 0.31 h in the epidermis. The Cmax in dermis
was 300.34 ± 54.79 µg/cm3 after 6.88 ± 0.88 h. Furthermore, the AUC0-24 of 1547.91 ± 203.43 h.µg/cm3
and 5869.17 ± 598.34 h.µg/cm3 were found in epidermis and dermis, respectively. With respect to
IVM NS profiles in the epidermis, the tmax was found to be 1.37 ± 0.29 h with a concentration of
108.02± 19.71µg/cm3. In the dermis layer, Cmax was found to be 372.07± 49.98µg/cm3 after 8.01± 1.23 h.
The AUC0-24 in epidermis and dermis were 2018.92 ± 342.32 h.µg/cm3 and 7122.40 ± 784.09 h.µg/cm3,
respectively. In addition, the time required for the drugs to be released from the MNs (lag time) in the
dermis were 0.294 ± 0.02 h, 0.354 ± 0.02 h, and 0.512 ± 0.04 h for DOX, ABZ-OX, and IVM, respectively.
The values of Cmax, AUC0–24, permeation rate and elimination rate in the epidermis was found to be
significantly higher (p-value < 0.05 each) than in dermis. In all cases, apart from tmax, the values of all
dermatokinetic parameters of drugs after MNs application were significantly higher (p-value < 0.05)
than needle-free patch application in epidermis and dermis. Considering the drug amount in the
actual needles of the arrays, 29.29 ± 4.65%, 31.54 ± 5.35%, and 34.54 ± 4.98% of DOX, ABZ-OX, and
IVM were retained in the dermis after 24 h administration.
The results presented here revealed that the incorporation of drugs in NS into dissolving MN
arrays significantly enhanced the delivery of those drug particles into the skin and led to the retention
of the drug particles in the dermis layer, a site replete with lymphatic capillaries [52] and hence, could
potentially target the Wolbachia and macrofilariae in the lymph nodes [3]. In addition, the drugs
that were not retained in the dermis layer might be taken up by the blood capillaries, which could
potentially kill the Wolbachia and microfilariae in the bloodstream [7]. A variety of published studies
have demonstrated that nanoparticles of ~100 nm accumulate in lymph nodes [53–55]. Furthermore,
work carried out in our research group demonstrated that incorporation of rhodhamine B-encapsulated
nanoparticles of <100 nm into dissolving MNs led to the delivery of this dye to the lymph nodes of
mice [56]. Accordingly, we propose that this combination delivery system could be used to target the
relevant drugs to the anatomic sites of filarial nematodes.
The skin distribution and deposition of all drugs were then investigated in order to measure
the distribution of the drug in full-thickness porcine skin. Figure 7g–i depict the amount of DOX,
ABZ-OX, and IVM detected per cm3 in a range different depths of skin after three application times,
namely, 1 h, tmax of dermis dermatokinetic profiles and 24 h. A close agreement results with the
dermatokinetic study were obtained in this study, showing that the distribution of all drugs was
significantly improved using MNs compared to needle-free patch. In the case of DOX distribution,
as can be observed in Figure 7g, after 1 h, the DOX concentration rose significantly between 0.1 and
0.3 mm depths. This concentration declined significantly at a mean depth of 0.9 mm. The drug was
not detected at a depth of 1.3 mm. After 6.8 h, the drug concentration reached a peak at a depth of
0.7 mm and was detected up to a depth of 1.5 mm. Finally, after 24 h, it was found that the drug was
still detected in a depth of 1.5 mm and hit the highest point in a depth of 1.1 mm. With respect to
ABZ-OX distribution (Figure 7h), there was a sharp increase in drug concentration between 0.1 mm
and 0.3 mm depth after 1 h and 3.4 h. Furthermore, the drug concentration in the skin decreased
dramatically and reaching the lowest concentration at a depth of 1.5 mm and 1.3 mm after 1 h and
3.4 h, respectively. The drug was not detected at 1.5 mm following a 1 h application time. After 24 h,
the drug concentration remained unchanged between a depth of 0.1 mm and 1.1 mm. The maximum
drug concentration was found in 1.3 mm depth and the drug concentration slightly decreased in a
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depth of 1.5 mm. In terms of IVM distribution (Figure 7i), 1 h application time exhibited the same
trend as the ABZ-OX concentration after 1 h. The maximum concentration was found in a depth of
0.9 mm and detected until 1.5 mm after 8 h. After 24 h, the concentration increased from a depth
of 0.1 mm to 0.7 mm and despite slight fluctuation, the drug concentration declined significantly
until a depth of 1.5 mm. On the other hand, all drugs were only detected until 0.5 mm after 24 h
application of the needle-free patch, indicating the ability of MNs to improve the penetration of the
drugs. In all cases, it was found that the drugs were detected in the deeper layers of the skin than MNs
height (500 µm), representing the movement of drugs in the skin. The great distribution of drugs after
intradermal administration using MNs in combination with NS approach could potentially lead to
the high possibility of lymphatic capillaries in dermis layer to take up the particles. With respect to
the concentration of these drugs required to kill filarial nematodes, it was reported that 40 µg/mL of
DOX [12], 26.53 µg/mL of ABZ [57], and 170 µg/mL of IVM [58] were able to kill Brugia malayi in vitro
after 7 days, 16 days, and 4 days, respectively. These concentrations were around 2–10 times lower
than the Cmax obtained in the dermatokinetic study. However, further studies are now required to
determine the concentrations of drugs which reach the infection site in vivo.
Figure 7. The drug concentration and time profile of DOX in epidermis (a) and dermis (b), DEC in
epidermis (c) and dermis (d), and ABZ-OX in epidermis (e) and dermis (f) layers of excised full-thickness
neonatal porcine skin, following the application of MN, in comparison with the application of free-needle
patches (means ± S.D., n = 3). The concentrations of drugs in a different layer of neonatal porcine
skin, following the application of MN containing (g) DOX NS; (h) ABZ-OX NS, and (i) IVM NS, in
comparison with the free-needle patch (means ± S.D., n = 3).
Taken together, the results presented here, combined with evidence reported in other published
studies, indicate that the unique delivery approach of combining NS into dissolving MN, leads
to successful intradermal delivery and drug retention in the dermis. The overriding benefit of the
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facilitated delivery approach we have reported here, compared to conventional oral administration, lies
in the capacity for drug retention in the skin which could potentially lead to targeting of the lymphatic
system when infected with filarial nematodes. Following on from these findings, further studies are
now necessitated to investigate the in vivo lymphatic delivery capabilities of this system, in order to
investigate the rate of which the NS is taken by the lymphatic system.
4. Conclusions
This study investigated the potential of dissolving MNs, used in combination with NS, to assist in
the targeted delivery of DOX, ABZ-OX, and IVM to the dermis layer of skin. Several optimization
steps were carried out to develop the NS formulation. PVP and SLS, utilized as stabilizers for DOX,
and PF127 used as a stabilizer for ABZ-OX and IVM resulted in the successful formulation of NS with
small particle sizes (<100 nm) and negative charges. The utilization of these NS enhanced the release
of the drugs in vitro with the results of the dermatokinetic studies providing proof of principle for
the intradermal delivery of antifilariasis drugs which could, in time, have positive implications in
the clinical treatment of LF. Before this novel delivery system can achieve patient benefit, however,
further comprehensive studies are required, including in vivo pharmacokinetic, lymphatic uptake,
and pharmacodynamic studies in an appropriate model system. Furthermore, patient usability and
acceptability must be determined in order to fully exploit the potential applications of this approach.
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